Abstract

Classic Hodgkin lymphoma (cHL) is characterized by a rich immune microenvironment as the main tumor component. It involves a broad range of cell populations, which are largely unexplored, even though they are known to be essential for growth and survival of Hodgkin and Reed–Sternberg cells. We profiled the gene expression of 25 FFPE cHL samples using NanoString technology and resolved their microenvironment compositions using cell-deconvolution tools, thereby generating patient-specific signatures. The results confirm individual immune fingerprints and recognize multiple clusters enriched in refractory patients, highlighting the relevance of: (1) the composition of immune cells and their functional status, including myeloid cell populations (M1-like, M2-like, plasmacytoid dendritic cells, myeloid-derived suppressor cells, etc.), CD4-positive T cells (exhausted, regulatory, Th17, etc.), cytotoxic CD8 T and natural killer cells; (2) the balance between inflammatory signatures (such as IL6, TNF, IFN-γ/TGF-β) and MHC-I/MHC-II molecules; and (3) several cells, pathways and genes related to the stroma and extracellular matrix remodeling. A validation model combining relevant immune and stromal signatures identifies patients with unfavorable outcomes, producing the same results in an independent cHL series. Our results reveal the heterogeneity of immune responses among patients, confirm previous findings, and identify new functional phenotypes of prognostic and predictive utility.

Details

Title
Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma
Author
Menéndez, Victoria 1 ; Solórzano, José L. 2 ; García-Cosío, Mónica 3 ; Alonso-Alonso, Ruth 4 ; Rodríguez, Marta 4 ; Cereceda, Laura 2 ; Fernández, Sara 2 ; Díaz, Eva 1 ; Montalbán, Carlos 5 ; Estévez, Mónica 5 ; Piris, Miguel A. 4 ; García, Juan F. 6 

 Fundación MD Anderson International España. Madrid, Translational Research, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543) 
 Fundación MD Anderson International España. Madrid, Translational Research, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543); MD Anderson Cancer Center Madrid, Pathology Department, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543) 
 Hospital Universitario Ramón y Cajal, Pathology Department, Madrid, Spain (GRID:grid.411347.4) (ISNI:0000 0000 9248 5770) 
 IIS Hospital Universitario Fundación Jiménez Díaz, Pathology Department, Madrid, Spain (GRID:grid.419651.e) (ISNI:0000 0000 9538 1950); ISCIII, Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) 
 MD Anderson Cancer Center Madrid, Hematology Department, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543) 
 Fundación MD Anderson International España. Madrid, Translational Research, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543); MD Anderson Cancer Center Madrid, Pathology Department, Madrid, Spain (GRID:grid.428844.6) (ISNI:0000 0004 0455 7543); ISCIII, Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) 
Pages
710
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2911130259
Copyright
© The Author(s) 2024. corrected publication 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.